Author: admin

Hepatocellular Carcinoma Market to Register Incremental Growth During the Forecast Period | Eli Lilly, Merck, Genetech, GlaxoSmithKline, Bristol-Myers Squibb

“Hepatocellular Carcinoma Market”
DelveInsight’s “Hepatocellular Carcinoma Market Insights, Epidemiology, and Market Forecast — 2032” report delivers an in-depth understanding of the Hepatocellular Carcinoma, historical and forecasted epidemiology as well as the Hepatocellular Carcinoma (HCC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The dynamics of Hepatocellular Carcinoma market is anticipated to change in the coming years owing to increased Research and Development (R&D) activities in the therapeutics market, expected introduction of emerging therapies with improved efficacy, label-expansion of approved therapies, more awareness initiatives programs, improvement in the diagnosis rate, and increased patient pool.

The pipeline of Hepatocellular Carcinoma is very robust, many potential therapies are being investigated for the treatment of Hepatocellular Carcinoma, and it is safe to predict that the treatment space will experience a significant impact on the market during the forecast period.

Some of the leading pharma and biotech giants such as H3 Biomedicine, Genoscience Pharma, Kymab, Sanofi, Exelixis, and various others are involved in developing therapies for Hepatocellular Carcinoma. Of the emerging therapies and combination therapies, one of the most anticipated products to get launched is cabozantinib in combination with atezolizumab. Apart from this, several other molecules are in the mid to late stages, such as DKN-01, Cabozantinib S-malate with Pembrolizumab, H3B-6527, and others. 

DelveInsight’s “Hepatocellular Carcinoma (HCC) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Hepatocellular Carcinoma market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Hepatocellular Carcinoma market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Hepatocellular Carcinoma Overview

Hepatocellular Carcinoma (HCC) is characterized by liver tumors that are not amenable to local treatments due to disease extent or recurrence post-local therapies. Advanced HCC typically occurs in patients with significant underlying liver disease, rendering them less tolerant to systemic chemotherapy.

While HCC usually doesn’t metastasize, when it does, it commonly spreads to the lungs and bones. These metastatic cancers are widespread and cannot be surgically removed. Symptoms of HCC can vary widely among individuals and may not directly correlate with cancer stage. Some symptoms include Gynecomastia, Erythrocytosis, High cholesterol, Hypercalcemia, and Hypoglycemia.

Hepatocellular Carcinoma (HCC) Market Key Facts

  • According to Surveillance, Epidemiology, and End Results (SEER), in the US, the incidence rate of Hepatocellular Carcinoma and Intrahepatic bile duct cancer was 9.0 per 100,000 which is estimated to be around 42,230 newly diagnosed cases in 2021, and the mortality rate was 6.6 per 100,000 per year, and the 5-year survival rate was 20.3%. Of them, the stage-wise incident cases of Hepatocellular Carcinoma and intrahepatic bile duct cancer were localized (45%), Regional (26%), Distant (18%), and Unknown (11%). 

  • According to the Global Cancer Observatory, in the 7MM, the ASR incident rate of liver cancer is 7.4/100,000, which is estimated to be around 135,533 new cases in 2020, and the ASR mortality rate of liver cancer is 4.8/100,000, which is estimated to be around 100,793 number of deaths in 2020. 

  • On November 2, 2022, Omega Therapeutics, Inc. (“Omega”) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for OTX-2002, the company’s first-in-class epigenomic controller engineered to downregulate c-Myc (MYC), for the treatment of hepatocellular carcinoma (HCC).

  • On October 19, 2022, Tvardi Therapeutics, Inc. (“Tvardi”) announced that its lead product, TTI-101, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed/refractory locally advanced, unresectable, or metastatic hepatocellular carcinoma (HCC).

  • On October 11, 2022, Elevar Therapeutics announced a positive pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) for its investigational drug rivoceranib in combination with camrelizumab as a treatment option for hepatocellular carcinoma (HCC).

Hepatocellular Carcinoma (HCC) Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Hepatocellular Carcinoma market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Hepatocellular Carcinoma market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Hepatocellular Carcinoma (HCC) Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders. 

The Report Covers the Hepatocellular Carcinoma Epidemiology Segmented by –

  • Total Incident Cases of Hepatocellular Carcinoma in the 7MM (2019-32)

  • Total Treated Cases of Hepatocellular Carcinoma in the 7MM (2019-32)

  • Stage-wise patients of Hepatocellular Carcinoma in the 7MM (2019-32)

Hepatocellular Carcinoma (HCC) Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hepatocellular Carcinoma market or expected to be launched during the study period. The analysis covers the Hepatocellular Carcinoma market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Hepatocellular Carcinoma pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Hepatocellular Carcinoma Market Will Evolve and Grow by 2032 @ https://www.delveinsight.com/sample-request/hepatocellular-carcinoma-market

Hepatocellular Carcinoma (HCC) Therapeutics Analysis

There are currently six FDA-approved immunotherapy options for Hepatocellular Carcinoma. Several other immunotherapies are currently being tested in Hepatocellular Carcinoma clinical trials, including oncolytic viruses and adoptive cell therapy. Hence, the therapy market also includes AVASTIN (bevacizumab), a targeted antibody that targets the VEGF-A pathway; approved, in combination with atezolizumab, as a first-line treatment for subsets of patients with advanced Hepatocellular Carcinoma.

Pharmaceutical companies are working toward developing potential therapies for Hepatocellular Carcinoma (HCC) to fulfill the unmet medical needs of the currently used therapeutics. There are approx. 80+ key companies which are developing therapies for Hepatocellular Carcinoma. Currently, Sinocelltech is leading the therapeutics market with its Hepatocellular Carcinoma drug candidates in the most advanced stage of clinical development among all the key players.

The Leading Companies in the Hepatocellular Carcinoma (HCC) Therapeutics Market Include:

  • Sinocelltech

  • AVEO Oncology

  • Oxford BioTherapeutics

  • Beijing SyngenTech

  • Surface Oncology

  • Novartis Oncology

  • Array BioPharma

  • Taizhou Hanzhong Pharmaceuticals

  • Akeso Biopharma

  • Innovent Biologics

  • Eli Lilly and Company

  • Shanghai Henlius Biotech

  • Chugai Pharmaceutical

  • CStone Pharmaceuticals

  • Jiangsu Hengrui Medicine

  • Shenogen Pharma

And Many More

Hepatocellular Carcinoma (HCC) Therapies Covered in the Report Include:

  • Tivozanib: AVEO Oncology

  • SCT-I10A: Sinocelltech

  • H3B-6527: H3 Biomedicine

  • GNS561: Genoscience Pharma

  • Exelixis: Cabozantinib

  • SAR445256 (also known as Alomfilimab, and formerly as KY1044): Kymab and Sanofi

And Many Others

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @ https://www.delveinsight.com/sample-request/hepatocellular-carcinoma-market

Table of Contents

1. Key Insights

2. Executive Summary 

3. Hepatocellular Carcinoma Competitive Intelligence Analysis

4. Hepatocellular Carcinoma Market Overview at a Glance

5. Hepatocellular Carcinoma Disease Background and Overview

6. Hepatocellular Carcinoma Patient Journey

7. Hepatocellular Carcinoma Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Hepatocellular Carcinoma Treatment Algorithm, Current Treatment, and Medical Practices

9. Hepatocellular Carcinoma Unmet Needs

10. Key Endpoints of Hepatocellular Carcinoma Treatment

11. Hepatocellular Carcinoma Marketed Products

12. Hepatocellular Carcinoma Emerging Drugs and Latest Therapeutic Advances

13. Hepatocellular Carcinoma Seven Major Market Analysis

14. Attribute Analysis

15. Hepatocellular Carcinoma Market Outlook (In US, EU5, and Japan)

16. Hepatocellular Carcinoma Access and Reimbursement Overview

17. KOL Views on the Hepatocellular Carcinoma Market

18. Hepatocellular Carcinoma Market Drivers

19. Hepatocellular Carcinoma Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

Download the Sample PDF to Learn More About the Key Offerings of the Report @ https://www.delveinsight.com/sample-request/hepatocellular-carcinoma-market

Other Trending Healthcare Reports By DelveInsight

Hepatocellular Carcinoma Pipeline Insight

“Hepatocellular Carcinoma Pipeline Insight, 2024” report provides comprehensive insights about 80+ companies and 80+ drugs in the Hepatocellular Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products by stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hepatocellular Carcinoma Market to Register Incremental Growth During the Forecast Period | Eli Lilly, Merck, Genetech, GlaxoSmithKline, Bristol-Myers Squibb

Metastatic Colorectal Cancer Pipeline 2024 | Pfizer, Sanofi, Taiho Pharma, Ono Pharma, Hutchison Medipharma, Isofol Medical, Sumitomo Dainippon Pharma, G1 Therapeutics, Merck, AB Science

“Metastatic Colorectal Cancer Pipeline Insight 2024”
As per DelveInsight’s assessment, globally, about 140+ key pharma and biotech companies are working on 140+ pipeline drugs in the Metastatic Colorectal Cancer therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Apart from the already existing players such as Pfizer, Sanofi, Taiho Pharma, Ono Pharma, along with many others, there are several emerging key players which are expected to change the Metastatic Colorectal Cancer treatment scenario in the coming years owing to the positive outcomes of the emerging pipeline candidates in their developmental stage, which includes Hutchison Medipharma, Isofol Medical, Sumitomo Dainippon Pharma, G1 Therapeutics, Merck, AB Science, Pfizer, Daiichi Sankyo/Astrazeneca, Merck/Eisai, Mirati Therapeutics, Merck, Cardiff Oncologyalong and several others.

“Metastatic Colorectal Cancer Pipeline Insight, 2024” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Metastatic Colorectal Cancer Market. 

The Metastatic Colorectal Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. 

The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Metastatic Colorectal Cancer Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for the treatment of Metastatic Colorectal Cancer and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Metastatic Colorectal Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Route of Administration

Metastatic Colorectal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as – 

  • Oral

  • Parenteral

  • Intravenous

  • Subcutaneous

  • Topical

Molecule Type

Products have been categorized under various Molecule types, such as –

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

Metastatic Colorectal Cancer Emerging Therapies Mechanism of Action (MOA) Types:

  • ATP binding cassette transporter subfamily G member 2 inhibitors

  • KRAS protein inhibitors 

  • Epidermal growth factor receptor antagonists

  • Polo-like kinase 1 inhibitor

  • Cyclin-dependent kinase 4 inhibitors

  • Immunostimulants

  • Interleukin-15 receptor agonists

  • Immunologic cytotoxicity; T lymphocyte replacements

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Recent Clinical, Commercial and Regulatory Developments in the Metastatic Colorectal Cancer Market

  • On 11 May 2021, Shanghai Henlius Biotech and NeuPharma entered into a drug technology license agreement. NeuPharma will grant the Company a sublicensable exclusive license for related licensed patents and licensed know-how necessary or reasonably useful for the Company to research, develop, produce and commercialize the Licensed Product within the Licensed Territory (China).

  • In November 2021, the US FDA granted a fast-track designation to arfolitixorin as a potential therapeutic option for patients with metastatic colorectal cancer (mCRC). This serves as a strong external validation of arfolitixorin’s potential to benefit patients with this devastating disease.

  • In January 2022, Gritstone bio, Inc. announced that the first patient was enrolled for inclusion in the Phase 2/3 GRANITE-CRC-1L trial. The trial evaluates the individualized neoantigen vaccine GRANITE in combination with immune checkpoint blockade for the first line (1L) maintenance treatment of newly diagnosed patients with metastatic, microsatellite-stable colorectal cancer (MSS-CRC). This trial has registrational intent and has been discussed previously with the FDA.

Learn How the Ongoing Clinical & Commercial Activities will Affect the Metastatic Colorectal Cancer Therapeutic Segment @ https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-pipeline-insight

Metastatic Colorectal Cancer Therapeutics Landscape

The goal of treatment for metastatic colorectal cancer is usually to prolong life and relieve or prevent symptoms. Treating colon cancer that has spread to other organs often requires a combination of different treatments. These may include surgery, chemotherapy, image-guided therapies, such as MRI and CT, radiation therapy, targeted therapies, and immunotherapy.

To improve the treatment scenario, there are approx. 140+ key companies developing therapies for Metastatic Colorectal Cancer. G1 Therapeutics is leading the therapeutics market with its Metastatic Colorectal cancer drug candidates in the most advanced stage of clinical development.

Leading Companies in the Metastatic Colorectal Cancer Therapeutics Market Include:

G1 Therapeutics, Amgen, Qilu Pharmaceutical, Eisai Co Ltd, Merck Sharp & Dohme, Mirati Therapeutics, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd., Shanghai Henlius Biotech, Amarin Corporation, Mologen, Sumitomo Dainippon Pharma Oncology, Celltrion, Merck Sharp & Dohme, Jiangsu Hengrui Medicine, Suzhou Zelgen Biopharmaceuticals, Mabpharm Limitied, Boehringer Ingelheim, Chia Tai Tianqing Pharmaceutical, Isofol Medical, Suzhou Suncadia Biopharmaceuticals Ltd/ Jiangsu Hengrui Medicine, AB Science, Gritstone Bio, Inc, Daiichi Sankyo, Novartis, Merck Sharp & Dohme, Sunshine Guojian Pharmaceutical, Pfizer, Merck KGaA, Jiangsu HengRui Medicine Co., Ltd., ALX Oncology, Immunovative Therapies, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Precision Biologics, Sanofi, GC Pharma, VAXIMM, AstraZeneca, Yooyoung Pharmaceutical, Med Pacto Inc., Exelixis, GlaxoSmithKline, Bristol Myers Squibb, Merck Sharp & Dohme, Bavarian Nordic, Maxinovel Pharmaceuticals, Shanghai Henlius Biotech, Novartis, Zucero Therapeutics, Innovent Biologics, Scandion Oncology, Merck Sharp & Dohme Corp., AbbVie, Beijing Biostar Technologies, Seagen Inc, Merck KGaA, Teclison Ltd, Symphogen A/S, Sichuan Baili Pharmaceutical; SystImmune, Karyopharm Therapeutics, and several others.

Metastatic Colorectal Cancer Drugs Covered in the Report Include:

  • Trilaciclib: G1 Therapeutics

  • Famitinib: Jiangsu Hengrui Medicine

  • CMAB009: Mabpharm Limited

  • Trastuzumab Deruxtecan: Daiichi Sankyo

  • SCO-101: Scandion Oncology

  • BEY 1107: BeyondBio

  • Etrumadenant: Arcus Biosciences

  • RG6286: Roche

  • CYAD 101: Celyad Oncology

  • Sym004: Symphogen A/S

  • Onvansertib: Cardiff Oncology

  • PolyPEPI 1018: Treos Bio

  • MRTX849: Mirati Therapeutics

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @ https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-pipeline-insight

Table of Contents

1. Report Introduction

2. Executive Summary

3. Metastatic Colorectal Cancer Current Treatment Patterns

4. Metastatic Colorectal Cancer – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Metastatic Colorectal Cancer Late Stage Products (Phase-III)

7. Metastatic Colorectal Cancer Mid-Stage Products (Phase-II)

8. Metastatic Colorectal Cancer Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Metastatic Colorectal Cancer Discontinued Products

13. Metastatic Colorectal Cancer Product Profiles

14. Key Companies in the Metastatic Colorectal Cancer Market

15. Key Products in the Metastatic Colorectal Cancer Therapeutics Segment

16. Dormant and Discontinued Products

17. Metastatic Colorectal Cancer Unmet Needs

18. Metastatic Colorectal Cancer Future Perspectives

19. Metastatic Colorectal Cancer Analyst Review  

20. Appendix

21. Report Methodology

Download Sample PDF to Explore the Key Offerings of the Report: 

https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-pipeline-insight

Other Trending Healthcare Reports By DelveInsight

Metastatic Colorectal Cancer Market

“Metastatic Colorectal Cancer Market Insights, Epidemiology, and Market Forecast 2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Metastatic Colorectal Cancer market size, shares, and trends analysis in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan). 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Metastatic Colorectal Cancer Pipeline 2024 | Pfizer, Sanofi, Taiho Pharma, Ono Pharma, Hutchison Medipharma, Isofol Medical, Sumitomo Dainippon Pharma, G1 Therapeutics, Merck, AB Science

Ischemic Stroke Market to Exhibit Remarkable Growth During the Forecast Period | Boehringer Ingelheim Pharmaceuticals, Inc., Bayer AG, Bristol-Myers Squibb Company, Pfizer Inc., AstraZeneca

“Ischemic Stroke Market”
The dynamics of the Ischemic Stroke market are anticipated to change in the coming years, owing to the improvement in the diagnosis methodologies, rising awareness of the diseases, incremental healthcare spending across the world, and the expected launch of emerging therapies. Companies across the globe are working towards the development of new treatment therapies for Ischemic Stroke.

To re-address the current issues, the companies are currently shifting their focus toward this indication to meet the needs of the current market. Some of the key companies in the market include Athersys, Abbvie, Bristol-Myers Squibb, Lumosa Therapeutics, Acticor Biotech, and others. Several of the pipeline drugs are in late-stage clinical development and are designed to address this long-standing unmet need in ischemic stroke. The late-stage pipeline agents and one stem cell therapy (MultiStem) aim at improving clinical outcomes post-stroke when given in the acute phase of stroke. Additionally, substantive advances have been made in the acute management of ischemic stroke. Recent trials demonstrating the benefit of endovascular therapy have brought a new era in the treatment of stroke.

DelveInsight’s “Ischemic Stroke Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Ischemic Stroke market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Ischemic Stroke market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Ischemic Stroke Overview

Ischemic Stroke occurs when a clot obstructs blood flow in a brain artery. Clots, either thrombotic or embolic, form depending on their origin in the body. Thrombotic strokes, more prevalent, arise from clots within brain arteries. Embolic strokes result from clots or small plaque fragments breaking off from elsewhere, like the heart, traveling through the bloodstream, and lodging in narrower brain vessels.

Nearly half of all ischemic strokes stem from large vessel occlusion (LVO), the most severe type where clots block major arteries, impeding blood flow to significant brain areas. Family history of stroke or prior strokes heightens the risk, as does age, with men and blacks facing higher susceptibility compared to women and other ethnic groups, respectively.

Ischemic Stroke Market Key Facts

  • According to the World Health Organization (WHO), an estimated 15 million individuals worldwide suffer from stroke each year. Of these, 5 million die, and another 5 million are left permanently disabled.

  • As per the study conducted by Edward C Jauch et al. 2019, nearly 800,000+ people suffer from strokes each year in the United States, and 82–92% of these strokes are ischemic. Stroke is the fifth leading cause of adult death and disability.

  • As per the Stroke Association of UK 2018, up to 25% of Ischemic childhood strokes are linked to congenital heart disease.

  • As per Luciana Catanese et al. 2017, the incidence of Acute Ischemic Stroke is greater among women beginning with an increased risk in the perimenopausal period and continuing into older age groups.

  • As per American Stroke Association, about 87% of all strokes are ischemic strokes, in which blood flow to the brain is blocked.

  • Increased awareness regarding early manifestations of stroke and its causes is anticipated to positively influence market development over the forecast period. Implementation of smoking cessation by the government and other such initiatives are anticipated to boost demand for stroke diagnostics in the near future.

  • In July 2022, ACTICOR BIOTECH announced that it had received “PRIority Medicines” status from the European Medicines Agency (EMA) for its drug candidate, glenzocimab, for the treatment of patients with stroke. This status allowed Acticor Biotech to strengthen interactions and obtain early dialogues with regulatory authorities in order to confirm the clinical development plan for glenzocimab in the treatment of stroke.

  • In July 2022, NervGen Pharma announced the University of Cincinnati and Case Western Reserve University (CWRU) had published a pioneering preclinical study in the peer-reviewed scientific journal Cell Reports demonstrating that NervGen’s proprietary drug, NVG-291-R, promotes nervous system repair and significant functional recovery in a mouse model of severe ischemic stroke, even when treatment was initiated up to 7 days after onset.

Ischemic Stroke Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Ischemic Stroke market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Ischemic Stroke market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Ischemic Stroke Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders. 

The Report Covers the Ischemic Stroke Epidemiology Segmented by –

  • Total Prevalent Cases of Ischemic Stroke (IS) in the 7MM (2019-32)

  • Diagnosed and Treatable Cases of Ischemic Stroke (IS) in the 7MM (2019-32)

  • Age-specific Prevalent Cases of Ischemic Stroke (IS) in the 7MM (2019-32)

  • Gender-specific Prevalent Cases of Ischemic Stroke (IS) in the 7MM (2019-32)

Ischemic Stroke Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Ischemic Stroke market or expected to be launched during the study period. The analysis covers the Ischemic Stroke market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Ischemic Stroke pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Ischemic Stroke Market Will Evolve and Grow by 2032 @ https://www.delveinsight.com/sample-request/ischemic-stroke-market

Ischemic Stroke Therapeutics Analysis

Several major pharma giants are developing therapies for Ischemic Stroke. Currently, Athersys, Inc. is leading the therapeutics market with its Ischemic Stroke drug candidates in the most advanced stage of clinical development.

Leading Companies in the Ischemic Stroke Therapeutics Market Include Athersys, Inc., Tarveda Therapeutics, Lumosa Therapeutics, Teijin Pharma Limited, NC Medial Research Inc, Acticor Biotech, Meridigen Biotech Co., Ltd., GrandPharma (China) Co., Ltd., Suzhou Yabao Pharmaceutical R&D Co., Ltd., Prolong Pharmaceuticals, Nanjing Yoko Biomedical Co., Ltd, TrueBinding, Inc., GNT Pharma, Roche, DiaMedica Therapeutics Inc, aptaTargets, Bristol-Myers Squibb, NuvOX Pharma, Guangzhou Recomgen Biotech Co., Ltd., Jiangsu Simcere Pharmaceutical Co., Ltd., Genentech, Inc., Ever Supreme Bio Technology Co., Ltd., NoNO Inc., Pharming Technologies B.V., Biogen, Acticor Biotech, Avilex Pharma, SanBio, ZZ Biotech, Shin Poong Pharmaceutical, Prolong Pharmaceuticals, Revalesio, Stemedica Cell Technologies, StemCyte, Ninnion, Algernon Pharmaceuticals, and many others.

Ischemic Stroke Therapies Covered in the Report Include:

  • MultiStem: Athersys, Inc.

  • LT3001: Lumosa Therapeutics

  • Elezanumab: Tarveda Therapeutics

  • RNS60: Revalesio Corporation

  • BMS-986177: Bristol-Myers Squibb

  • Elezanumab: AbbVie

  • Glenzocimab: Acticor Biotech

And Many More 

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @ https://www.delveinsight.com/sample-request/ischemic-stroke-market

Table of Contents

1. Key Insights

2. Executive Summary 

3. Ischemic Stroke Competitive Intelligence Analysis

4. Ischemic Stroke Market Overview at a Glance

5. Ischemic Stroke Disease Background and Overview

6. Ischemic Stroke Patient Journey

7. Ischemic Stroke Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Ischemic Stroke Treatment Algorithm, Current Treatment, and Medical Practices

9. Ischemic Stroke Unmet Needs

10. Key Endpoints of Ischemic Stroke Treatment

11. Ischemic Stroke Marketed Products

12. Ischemic Stroke Emerging Drugs and Latest Therapeutic Advances

13. Ischemic Stroke Seven Major Market Analysis

14. Attribute Analysis

15. Ischemic Stroke Market Outlook (In US, EU5, and Japan)

16. Ischemic Stroke Access and Reimbursement Overview

17. KOL Views on the Ischemic Stroke Market

18. Ischemic Stroke Market Drivers

19. Ischemic Stroke Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

Download the Sample PDF to Learn More About the Key Offerings of the Report @ https://www.delveinsight.com/sample-request/ischemic-stroke-market

Other Trending Healthcare Reports By DelveInsight

Ischemic Stroke Pipeline Insight

“Ischemic Stroke – Pipeline Insight, 2023,” report provides comprehensive insights about 50+ companies and 50+ drugs in the Ischemic Stroke pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products by stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Ischemic Stroke Market to Exhibit Remarkable Growth During the Forecast Period | Boehringer Ingelheim Pharmaceuticals, Inc., Bayer AG, Bristol-Myers Squibb Company, Pfizer Inc., AstraZeneca

Oxygen Labs Awarded Best AI Marketing Agency in the United States by Stellar Business

Oxygen Labs, a trailblazer in the AI automation space, has been crowned “The Best AI Automation Agency in the United States” by Stellar Business. This accolade is a testament to the pioneering spirit and innovation that Oxygen Labs brings to the AI landscape, revolutionizing sales and customer service like never before.

In an era where digital marketing transcends traditional norms, Oxygen Labs has emerged as the undisputed champion. Recognized as the Best AI Marketing Agency in the United States by Stellar Business, Oxygen Labs has turned the world of AI on its head, using intelligent systems to re-engineer the marketing landscape.

Founded with the bold vision of transforming sales and customer service through AI, Oxygen Labs has created an industry benchmark. What once took human-powered teams 160 hours, Oxygen Labs does in minutes. It’s not just automation; it’s a marketing revolution.

“At Oxygen Labs, we’re in the business of building AI-driven solutions that supercharge efficiencies and turbocharge marketing,” says an Oxygen Labs spokesperson. “This award is a testament to our relentless pursuit of innovation and quality.”

Oxygen Labs has crafted a seamless customer journey, a streamlined process that rapidly propels prospects from “initial interest” all the way to “ready to purchase” faster and more efficiently than ever before. Their coveted Excellence Package, setting a new standard in interaction and conversion, is in hot demand.

In the Excellence Package, advanced AI Agents capable of making and receiving calls merges with their Omnichannel AI Texting Agents (a superpowered version of the traditional chatbot) and cutting-edge AI & Automation technologies. This powerful arsenal, capable of starting and then continuing conversations with customers across multiple platforms at any time during the sales process, slashes the buying process – turning what used to take months into weeks or even days. Oxygen Labs’ methodology targets efficiency, harnessing AI to elevate customer engagement to unprecedented levels.

At Oxygen Labs, personalized customer interactions underpin superior conversions. Their service suite aligns with the pulse of modern business, ensuring no engagement opportunity slips through the cracks. Automated agents and messaging platforms create a flawless lead nurturing process, seamlessly handling communication and arranging meetings.

Through their state-of-the-art AI solutions, Oxygen Labs is a shining beacon in the industry, fundamentally changing the way businesses interact with potential customers and secure conversions.

LinkedIn’s COO, Dan Shapiro, once mused, “Imagine every seller on your team being 30% more effective”. With Oxygen Labs, this is no longer imagination—it’s reality.

Oxygen Labs stands tall with an unwavering focus on customer success. They’ve transformed the client experience, from demo scheduling to post-launch support, making marketing and sales goals a breeze.

In a rapidly evolving digital world, Oxygen Labs drives the reinvention of AI automation benchmarks. This recognition cements their authority in the AI automation industry, gearing them to lead businesses into a future where every interaction is a profitable opportunity.

Agencies interested in partnering with Oxygen Labs to provide these solutions to their own clients should contact their Co-Founder, Andrew Naegele. Individuals can learn more about how Oxygen Labs is poised to change the game in sales and marketing on their official website and various social media platforms, including YouTube, Instagram, Facebook, Twitter (@OxygenLabsAi), LinkedIn, and TikTok (@OxygenLabsAi).

Media Contact
Company Name: Oxygen Labs
Contact Person: Andrew Naegele
Email: Send Email
Country: United States
Website: https://www.oxygenlabs.ai

Leading Beyond Connectivity: Stanley Okoro’s Innovation in Tech and Wildfire Management

Stanley Okoro, a visionary in technology and wildfire management, demonstrates an unwavering commitment to innovation and social responsibility, leveraging cutting-edge solutions and pioneering research to redefine the boundaries of technological advancement and inspire positive change globally.

The rapid technological advancement and pressing environmental challenges in today’s world call for individuals who are innovators and show exceptional leadership. Among these trailblazers is Stanley Okoro, a visionary figure whose remarkable contributions span telecommunications and wildfire management. Heralded for his pioneering initiatives in telecommunications, including the deployment of advanced networks and groundbreaking research in artificial intelligence (AI) and machine learning (ML), Stanley continues to redefine the boundaries of technological innovation.

Raised in Nigeria, Stanley’s journey is a testament to resilience and the transformative power of education. Rooted in the values of diligence and perseverance instilled by his parents, he embarked on a trajectory marked by notable achievements and unwavering commitment to excellence. Stanley’s contributions to the Information and Communication Technology (ICT) sector have been nothing short of remarkable. His tenure at Alcatel-Lucent and Nokia witnessed the implementation of transformative projects, such as the Glo-1 optical fiber network landing station, which catalyzed a paradigm shift in Africa’s digital landscape, fostering economic growth and connectivity.

His leadership as Technical Solutions Lead at Nokia propelled the deployment of 5G networks across the Middle East and Africa, heralding a new era of connectivity and enabling the proliferation of Internet of Things (IoT) technologies throughout the region. Additionally, his seminal MBA research project laid the groundwork for the successful integration of 5G technology across Africa, further solidifying his status as a visionary in the field.

Stanley’s current undertaking, however, addresses a pressing environmental challenge: proactive wildfire detection and management in the United States. Leveraging cutting-edge technologies such as AI, ML, and 5G, his initiative focuses on real-time monitoring and swift response mechanisms utilizing drones and IoT devices. By harnessing the power of data analytics, AI algorithms identify potential fire hazards preemptively, while 5G facilitates seamless communication among emergency responders, enhancing the efficacy of wildfire containment efforts.

In a recent interview, Stanley emphasized the pivotal role of research in driving technological innovation, advocating for collaboration between academia and industry to foster groundbreaking advancements. His unwavering dedication to innovation and social responsibility underscores a holistic approach to success, inspiring generations to come.

Beyond his professional endeavors, Stanley remains deeply invested in nurturing the next generation of leaders. Through mentorship programs and active engagement with various philanthropic organizations, he champions causes related to healthcare awareness and youth development, embodying the ethos of giving back to society.

With Stanley Okoro at the vanguard of innovation and social impact, the future holds promise for transformative advancements and positive societal change. Indeed, his journey stands as a testament to the enduring power of visionary leadership in shaping a brighter tomorrow for all.

Media Contact
Company Name: Stanley Okoro
Contact Person: Victor
Email: Send Email
Country: United States
Website: https://stanleychineduokoro.com

Embark on a North Carolina Adventure: Meet Eros, Currituck Outer Banks’s Nest Mustang

As stewards of Corolla and Currituck County, the local community is committed to safeguarding the beaches, historic sites, and the diverse wildlife that call this region home. Among the most cherished inhabitants are the Wild Mustangs, descendants of the horses brought by Spanish explorers in the 16th century. These iconic creatures roam freely in the expansive Currituck National Wildlife Refuge, captivating visitors with their grace and beauty. And now, they are thrilled to announce the arrival of a new member to the herd!

Little Eros made his debut in early February, marking the first foal of 2024 and bringing the total count of wild horses in the herd to 111. With spring in full swing, those planning a visit to the county’s beaches may have the chance to witness Eros and his peers frolicking along the shore during their stay.

Admire from Afar: Tips for Wildlife Etiquette

While encountering the Wild Mustangs can be a highlight of any trip to the Currituck Outer Banks, it’s crucial to respect their natural habitat and adhere to guidelines that ensure their well-being. Here are some essential rules to follow:

1. Maintain a safe distance: For the safety of both visitors and the horses, it’s imperative to keep a minimum distance of fifty feet from any Wild Mustangs. This distance helps minimize stress and allows the horses to go about their activities undisturbed.

2. Respect maternal bonds: Foals like Eros need time to bond with their mothers and integrate into the herd. Avoid any actions that may cause distress to the horses, as maternal aggression can occur when perceived threats are present.

3. Leash the pets: Keep furry companions leashed and under control at all times while on Corolla beaches. Unrestrained pets can startle the horses, leading to potential harm for both animals and humans.

4. Avoid feeding the horses: The Wild Mustangs primarily rely on natural vegetation for sustenance and should not be fed by visitors. Human food, such as apples and carrots, can be harmful to the horses and disrupt their diet.

Discover the Mustangs on a Guided Tour

For an enriching and safe experience with the Wild Mustangs, consider booking a guided horse sightseeing tour. Professional tour companies offer excursions to areas where the horses are frequently spotted, providing visitors with an up-close encounter while ensuring the horses’ welfare.

Whether lounging on the beach or embarking on a wildlife adventure, they invite everyone to explore the wonders of Corolla and Currituck County. Download the visitors’ guide to start planning the perfect getaway and embark on an unforgettable journey to discover the beauty of Wild Mustangs in their natural habitat.

About Corolla and Currituck County Tourism Board

The Corolla and Currituck County Tourism Board is dedicated to promoting and preserving the natural beauty and cultural heritage of Corolla and Currituck County, North Carolina. From pristine beaches and historic landmarks to diverse wildlife and outdoor adventures, the region offers something for every traveler.

Media Contact
Company Name: Currituck Outer Banks, NC
Contact Person: Alex Perry
Email: Send Email
Country: United States
Website: https://www.visitcurrituck.com/

Alice-SES Spearheads a Green Revolution in Finance: Investing with a Conscience

In a bold move that sets it apart from traditional financial service providers, Alice-SES has announced a groundbreaking initiative to couple financial investments with environmental stewardship in 2024. Going beyond its already innovative zero-fee investment platform, Alice-SES is introducing a new suite of eco-friendly investment options, including green bonds, ESG (Environmental, Social, and Governance) focused mutual funds, and sustainable IPOs from companies with a proven commitment to reducing their carbon footprint.

This initiative, dubbed “Green Investing with Alice-SES,” aims to not only provide investors with the opportunity to grow their wealth but also to contribute positively to the planet’s health. Recognizing the increasing concern among investors about climate change and the environmental impact of their investments, Alice-SES is leveraging its award-winning platform to offer investments that promise both financial returns and a positive environmental impact.

Alice-SES’s move is timely, aligning with a global shift towards sustainable investing. The platform’s introduction of green bonds and ESG-focused mutual funds offers investors a way to contribute to projects and companies that are leading the fight against climate change, from renewable energy projects to sustainable agriculture initiatives. Additionally, by selecting IPOs from companies with strong environmental credentials, Alice-SES enables investors to support businesses that are pioneering green technologies and solutions.

The Alice-SES MOBI 2.0 trading app and platform, known for its superior user experience, cutting-edge technology, and advanced trading features, will facilitate these green investment options seamlessly. Investors can now easily diversify their portfolios with investments that not only offer competitive returns but also align with their values regarding environmental sustainability.

To further solidify its commitment to sustainability, Alice-SES has pledged to allocate a portion of its profits from the green investment portfolio towards environmental conservation projects. This initiative not only exemplifies Alice-SES’s dedication to responsible investing but also sets a new standard for corporate environmental responsibility in the financial sector.

In celebration of this new venture, Alice-SES is planning a series of webinars and workshops aimed at educating investors about the benefits and impacts of green investing. These sessions will feature experts in sustainable finance, environmental scientists, and representatives from companies issuing green bonds and sustainable IPOs, providing a comprehensive view of the opportunities and challenges in aligning financial growth with environmental sustainability.

Alice-SES’s innovative approach to finance, marked by its zero-fee investment structure and now its green investment initiative, has positioned the platform as a leader in the evolution of the financial services industry. By offering a way for investors to achieve their financial goals while also contributing to a healthier planet, Alice-SES is truly investing with a conscience. For those interested in learning more about this revolutionary platform and its offerings, visiting the [Alice-SES official website](https://aliceses.com/) offers a gateway to smarter, more sustainable investing.

Disclaimer: This press release may contain forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies (including product offerings, regulatory plans and business plans) and may change without notice. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements.

Media Contact
Company Name: Alice-SES
Contact Person: Alice Loundre
Email: Send Email
Country: India
Website: https://aliceses.com

Plant-Based Protein Market Size, Share, Industry Overview, Trends, Growth Drivers, Business Opportunities, and Leading Players

“MarketsandMarkets™”
Plant-Based Protein Market by Source (Soy, Wheat, Pea, Canola Rice & Potato, Beans & Seeds, Fermented Protein), Type (Concentrates, Isolates, Textured), Form (Dry, Liquid), Nature (Conventional, Organic), Application and Region – Global Forecast to 2028

The global plant-based protein market is estimated to be valued at USD 13.3 billion in 2023 and is projected to reach USD 19.2 billion by 2028, at a CAGR of 7.7% from 2023 to 2028. In recent years, the global food industry has witnessed a significant shift in consumer preferences, with a growing demand for plant-based protein alternatives. This trend reflects changing consumer attitudes toward health, sustainability, and ethical considerations. Many consumers are becoming more health-conscious, looking for options that align with their dietary preferences and restrictions. Plant-based protein sources, such as tofu, legumes, and pea protein, are often perceived as healthier choices due to their lower saturated fat content and absence of cholesterol. Additionally, they are often rich in fiber and essential nutrients, making them attractive alternatives for those seeking to maintain a balanced diet.

Plant-Based Protein Market

Plant-Based Protein Market Trends

The plant-based protein market had been experiencing significant growth, driven by various factors such as increasing consumer awareness of health and sustainability, rising concerns about animal welfare, and the expanding availability of plant-based products. Here are some trends that were shaping the plant-based protein market:

1. Expansion of Product Offerings: Food companies were diversifying their plant-based protein product lines beyond traditional options like tofu and tempeh to include innovative alternatives such as pea protein, soy protein, seitan, and mycoprotein (derived from fungi).

2. Rise of Beyond Meat and Impossible Foods: Beyond Meat and Impossible Foods had emerged as key players in the plant-based protein market, offering realistic meat alternatives that appealed to both vegetarians/vegans and flexitarians.

3. Retail Penetration: Plant-based protein products were becoming increasingly available in mainstream retail outlets, including supermarkets, convenience stores, and online platforms. This increased accessibility was driving greater adoption among consumers.

4. Investment and Innovation: There was significant investment in research and development within the plant-based protein sector, leading to advancements in taste, texture, and nutritional profile of plant-based products. This included the development of plant-based alternatives for dairy products like milk, cheese, and yogurt.

5. Celebrity Endorsements and Partnerships: High-profile endorsements from celebrities and partnerships with popular restaurants and food chains were helping to promote plant-based protein products and broaden their appeal to a wider audience.

6. Health and Wellness: Growing concerns about health and wellness were driving consumers to seek out plant-based protein options as part of a balanced diet. Plant-based proteins were often perceived as healthier alternatives to animal-derived proteins due to their lower saturated fat content and higher fiber and micronutrient content.

7. Environmental Sustainability: Increasing awareness of the environmental impact of animal agriculture, including greenhouse gas emissions, deforestation, and water usage, was prompting consumers to choose plant-based protein options as a more sustainable choice.

8. Regulatory Changes and Labeling: Regulatory changes related to food labeling and marketing were impacting the plant-based protein market, with some jurisdictions implementing stricter regulations around terms like “meat” and “dairy” on plant-based products.

Plant-Based Protein Market Opportunities: Focus on aquatic plants as new & emerging sources of protein

Plant-based foods and beverages offer various health benefits and essential minerals; however, they can cause allergies in some individuals, which presents a challenge to market growth. For example, soybeans, despite their nutrient-rich profile, contain anti-nutritional components that can trigger allergies. Soy is part of the “Big Eight” allergens, alongside cow’s milk, eggs, peanuts, tree nuts, wheat, fish, and shellfish, responsible for 90% of food allergies. Soy allergy occurs when the immune system mistakenly identifies harmless soy proteins as harmful, leading to allergic reactions. Additionally, soy protein contains high levels of phytic acid, which may hinder the absorption of vital minerals like calcium, magnesium, copper, iron, and zinc, potentially causing symptoms such as itching, hives, bloating, diarrhea, nausea, and abdominal pain.

Another concern revolves around wheat, which has traditionally been a staple food providing essential nutrients. However, recent years have seen rising apprehensions about its adverse health effects, particularly in North America and Europe. Wheat gluten proteins can lead to various adverse reactions, including allergies, celiac disease, and non-celiac gluten sensitivity. Celiac disease, often beginning in infancy, results from an allergic reaction to gluten in the diet, leading to inflammation and damage to the small intestine’s inner lining. These allergies associated with specific plant-based ingredients are expected to limit the growth of the global plant-based protein market in the forecast period.

The North American market is projected to dominate the plant-based protein market.

The increasing demand for plant-based proteins in North America can be attributed to several factors. First, ethical considerations and growing consumer awareness regarding personal and environmental health have driven many people to adopt veganism and flexitarian diets, emphasizing the importance of sustainable and cruelty-free food choices.

Additionally, a report from the Plant Based Foods Association (PBFA) in March 2022 revealed that plant-based food retail sales in the United States reached USD 7.4 billion, surpassing total food retail sales. This impressive growth of 6.1% in 2021, despite supply chain disruptions and pandemic restrictions, has sparked a continued surge in demand for plant-based foods, offering significant business opportunities for plant-based protein ingredients.

Top Companies in the Plant-Based Protein Market

The key players in this market include Cargill, Incorporated (US), International Flavors & Fragrances Inc. (US), ADM (US), Ingredion Incorporated (US), Roquette Frères (France), Wilmar International Ltd. (Singapore), Glanbia plc (Ireland), Kerry Group PLC (Ireland), DSM (Netherlands), AGT Food and Ingredients (Canada), Burcon NutraScience Corporation (Canada), Emsland Group (Germany), PURIS (US), COSUCRA (Belgium), Tate & Lyle (UK), BENEO GmbH (Germany), SOTEXPRO (France), Shandong Jianyuan group (China), AMCO Proteins (US), Axiom Foods, Inc (US), Aminola (Netherlands), The Green Labs LLC. (US), Australian Plant Proteins Pty Ltd (Australia), ETChem (China), PROEON (India), Nutraferma, Inc. (US), MycoTechnology (US), European Protein A/S (Denmark).

Other players in the ecosystems are Batory Foods, Berkem Group, CHS Inc.,  Crown Soya Protein Group Company, Devansoy Inc., Fuji Oil Holdings, Gushen Biotechnology Group Co., Ltd., among others.

ADM (US)

Archer Daniels Midland Company, commonly referred to as ADM, specializes in the production and distribution of a wide range of products, including food ingredients, animal feed and feed ingredients, biofuels, and environmentally friendly alternatives to industrial chemicals. With a history spanning over a century, ADM maintains a diverse portfolio of businesses that spans the entire agricultural value chain. One of ADM’s significant competitive advantages is its capability to efficiently source, process, and distribute agricultural commodities such as grains, oilseeds, and other raw materials. This is facilitated by its extensive network of origination facilities, processing plants, and logistics capabilities, enabling the company to effectively connect farmers and producers with customers worldwide.

ADM is recognized as a global leader in the nutrition sector and has a rich history of innovation in plant-based proteins, with a track record spanning more than 75 years. It is also one of the largest soybean processors globally. The company operates through four major segments: Ag services and oilseeds, carbohydrate solutions, nutrition, and others. Under the nutrition segment, ADM offers plant protein products primarily utilized in various food applications, including bakery, snacks, confectionery, and cooking. ADM produces plant-based proteins from sources like peas, soy, and wheat, which have diverse applications in dairy and meat alternative products, as well as feed products.

ADM’s global presence extends across North America, South America, Europe, Asia Pacific, and Africa. The company has established a robust global supply chain network to maintain consistent product quality. This network includes 450 crop procurement locations, over 330 food and feed ingredient manufacturing facilities, 62 innovation centers, and an extensive crop transportation system.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=14715651

Cargill, Incorporated (US)

Cargill, Incorporated, founded in 1865, has grown to become one of the largest privately owned firms in the United States, with a strong global presence. The firm manufactures and distributes food ingredients, bio-industrial goods, animal nutrition and health solutions, protein, salt, agricultural supply chain services, financial services, and metals. Cargill is comprised of 75 corporate units divided into four major segments: agricultural, food, financial services, and industrial products. Its plant-based protein offerings are classified as food and drinks and may be found in a variety of food goods such as bread items, snacks, confectionery, and culinary components.

Cargill’s R&D facilities are strategically placed across Europe and North America. The organization provides services across Africa, Europe, Asia, Latin America, North America, and the Middle East, among other places. Cargill operates in 70 countries through its subsidiaries and affiliates, providing a strong worldwide network that spans North America, South America, Europe, Asia Pacific, and Africa. Cargill Meat Solutions (US), Cargill Enterprises Inc. (Russia), Cargill Asia Pacific Holdings Pte Limited (Singapore), Cargill RSA (Pty) Limited (South Africa), Cargill Espaa SA. (Spain), and Cargill Nordic A/S (Sweden) are some of the company’s noteworthy subsidiaries.

International Flavors & Fragrances Inc.  (US)

In February 2021, International Flavors & Fragrances Inc. and Dupont’s Nutrition and Biosciences merged, resulting in the continuance of the combined firm under the name International Flavors & Fragrances Inc. This firm manufactures flavors, perfumes, and cosmetic actives on a global scale.

International Flavors & Fragrances Inc. is divided into four business segments. The company’s “nourish” business offers a diverse and unique range of natural-based ingredients designed to improve the nutritional content, texture, and functioning of a variety of food and beverage items, including drinks, dairy products, baked goods, confectionery, and culinary applications. The health & biosciences division focuses on the research and development of innovative biotechnology-derived solutions such as enzymes, food cultures, probiotics, and specialized ingredients with applications in both food and pharmaceuticals.

The scent segment specializes in creating fragrance compounds, fragrance ingredients, and cosmetic components used in high-quality perfumes as well as popular household and personal care products. Finally, the pharma solutions segment offers a broad range of pharmaceutical excipients derived from cellulosic and seaweed sources. These four segments together comprise the company’s diverse business portfolio, serving various industries and providing innovative solutions for a range of applications. Additionally, the company offers plant-based protein products within its nourish category.

Make an Inquiry: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=14715651

Ingredion (US)

Ingredion, a multinational corporation based in the United States, specializes in the production of starch, modified starches, nutritional ingredients, and sweeteners. The company’s operations are organized into five primary business segments: food, beverage, animal nutrition, brewing, and other categories. Within its food and beverage segments, Ingredion offers plant-based protein products that are used in various applications, including animal feed, performance nutrition, dairy, and meat-alternative products.

Ingredion maintains a global presence, serving customers in more than 120 countries across various regions, including North America, South America, Europe, Asia-Pacific, and the Middle East & Africa. Some of its notable subsidiaries include TIC Gums Inc (US), Kerr Concentrate Inc (US), National Starch Food Innovation (US), and Perford Corporation (US).

The company faces formidable competition from prominent industry players such as DuPont (US), Glanbia plc (Ireland), and ADM (US).

Roquette Frères (France)

The French business Roquette Frères is a major leader in the plant-based protein market. Biopharma, pharma & nutraceuticals, cosmetics, food & nutrition, animal nutrition, industrial markets, and NUTRALYS plant protein are the company’s seven primary business sectors. Under the NUTRALYS plant protein category, Roquette offers plant-based protein products derived from diverse sources such as peas, wheat, and faba beans. These proteins have several applications in dairy and meat substitutes, as well as in sports nutrition.

Geographically, Roquette has a presence in North America, Europe, and Asia. It serves a customer base that spans more than 45 countries, including the United States, China, Korea, Japan, India, Russia, Canada, Spain, Germany, and the United Kingdom. Some of its notable subsidiaries include Roquette Korea Ltd (Korea), Roquette America Inc (US), Sethness Products Company (US), Bacel Eatmoquimica Ltda (Brazil), Roquette Co Ltd (China), and Roquette UK Ltd (UK).

The company has a presence in Australia, China, North America, and Southeast Asia. The company operates throughout Australia and New Zealand.

Key Questions Addressed by the Plant-Based Protein Market Report:

Which region is projected to account for the largest share in the dairy alternatives market?

What is the current size of the global plant-based protein market?

Which are the key players in the market?

What are the factors driving the plant-based protein market?

Which segment by source accounted for the largest plant-based protein market share?

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=14715651

About MarketsandMarkets™

MarketsandMarketsTM has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/plant-based-protein-market-14715651.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Plant-Based Protein Market Size, Share, Industry Overview, Trends, Growth Drivers, Business Opportunities, and Leading Players

Smart Locker Market worth $3.6 Billion by 2028, at a CAGR of 11.6%

“Smart Locker Market”
The Smart Locker Market Size is expected to reach USD 3.6 billion by 2028 from USD 2.1 billion in 2023 to grow at a CAGR of 11.6% during the forecast period.

The report “Smart Locker Market by Offering (Hardware, Software, Services), Technology (RFID, Electronic, Mobile, Biometric, Cloud), Deployment (Indoor, Outdoor), Application (Day, Parcel, Staff, Asset Management), End-Use Industry, Region – Global Forecast to 2028” The global smart locker market is expected to be valued at USD 2.1 billion in 2023 and is projected to reach USD 3.6 billion by 2028; it is expected to grow at a CAGR of 11.6 % from 2023 to 2028.

The need for smart lockers arises from the evolving demands of modern lifestyles, driven by factors such as the surge in e-commerce activities, the imperative for contactless solutions amidst the pandemic, last-mile delivery challenges in urban environments, advancements in technology like IoT and RFID integration, and the growing emphasis on sustainable and secure parcel management practices. These lockers cater to convenience, efficiency, and security demands in package delivery and storage, adapting to the changing dynamics of consumer behavior and the technological landscape.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=209948292

Browse 157 market data Tables and 58 Figures spread through 205 Pages and in-depth TOC on “Smart Locker Market by Offering (Hardware, Software, Services), Technology (RFID, Electronic, Mobile, Biometric, Cloud), Deployment (Indoor, Outdoor), Application (Day, Parcel, Staff, Asset Management), End-Use Industry, Region – Global Forecast to 2028”

View detailed Table of Content here – https://www.marketsandmarkets.com/Market-Reports/smart-lockers-market-209948292.html

Smart Locker Market

The software segment is expected to grow fastest during the forecast period.

The software segment is expected to grow fastest in the smart locker market during the forecast period. This is primarily because of the increasing demand for advanced solutions that promote storage management efficiency, security, and convenience. The rise of contactless and IoT-driven technologies has spurred the adoption of smart locker software, particularly in response to the evolving needs of workplaces and public spaces. The surge in e-commerce and the secure parcel delivery solutions market further contribute to the demand for sophisticated software offerings that seamlessly integrate with smart locker systems. Additionally, the growing emphasis on data analytics and real-time monitoring capabilities enhances the appeal of smart locker software, allowing administrators to gain valuable insights into usage patterns and security. The versatility of these software solutions, catering to a wide range of applications, including asset tracking, user authentication, and access management, is also a driving factor in their increasing market presence.

The office segment is projected to grow significantly during the forecast period.

The growing need for smart lockers in the office sector is driven by a convergence of factors reshaping contemporary work environments. Smart lockers offer an efficient and organized solution for staff/employees to securely store personal belongings, particularly relevant in flexible work arrangements where dedicated workspaces may be limited. The demand for contactless solutions positions smart lockers as a touchless and secure method for employees to access their belongings. These lockers also address the increasing volume of package deliveries in office settings, streamlining the management process. The reduced administrative burden, seamless integration with access control systems, and alignment with green initiatives further solidify smart lockers as a pivotal element in fostering modern and tech-savvy office environments.

Asia Pacific is expected to grow fastest throughout the forecast period.

In 2022, the largest share of the smart locker market was held by North America. The market is driven by developments in smart lockers by various North American-based companies such as Gibraltar Industries, Pitney Bowes, Inc., Bell and Howell LLC, etc. The regional market for Asia Pacific is expected to grow at the highest CAGR during the forecast period, attributed to the strong foothold for commercial, office, residential, education, healthcare, and logistics in China, Japan, and South Korea. The rapid growth of e-commerce giants like Alibaba and JD.com has increased the need for efficient parcel delivery solutions, driving the demand for smart lockers as secure pickup points. Tech-savvy regions such as Beijing are quick to adopt technological innovations. Smart lockers, equipped with advanced features like IoT and RFID integration, align with the tech-driven preferences of these urban centers. In addition, the growing population and the rising government investments in infrastructural development in countries in the Asia Pacific region are expected to drive the growth of the smart locker market further soon.

Key Players

The smart locker market includes significant Tier I and II players such as Ricoh (Japan), Pitney Bowes, Inc (US), ASSA ABLOY (Sweden), Quadient (France), Gibraltar Industries (US), Hollman Inc (US), Bell and Howell, LLC (US), Cleveron (Estonia), InPost SA (Poland) and so on are some of the key players in the smart locker market.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/smart-lockers-market-209948292.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Smart Locker Market worth $3.6 Billion by 2028, at a CAGR of 11.6%

Collagen Market Size, Share, Industry Overview, Trends, Growth Drivers, Business Opportunities, and Leading Players

“MarketsandMarkets™”
Collagen Market by Product Type, Applications (Nutritional Products, Food & Beverages Products, Pharmaceuticals Products, Cosmetics & Personal care Products, textile), Source, Form, Type, Extraction process and Region – Global Forecast to 2030

The global collagen market is on a trajectory of significant expansion, with an estimated value projected to reach USD 7.4 billion by 2030 from the 2023 valuation of USD 5.1 billion in 2023, displaying a promising Compound Annual Growth Rate (CAGR) of 5.3%. The increasing demand for collagen products is driven by their widespread application across diverse sectors such as healthcare, cosmetics, and food and beverages. Gelatin and hydrolyzed collagen, in particular, play essential roles in various industries. Collagen supplements, renowned for their versatile uses, find application in cosmetic procedures, anti-aging treatments, and aesthetic medications, contributing to skin moisture retention and preventing premature aging. Moreover, collagen holds significance in pharmaceutical applications, serving as a vital component in the production of membranes and sponges for drug delivery systems. Notably, the natural degradation of these materials ensures safe disposal without posing environmental risks. The upward trajectory in demand is further propelled by technological advancements within the healthcare industry, enhancing the overall efficiency of collagen products.

Collagen Market

Collagen Market Trends

The collagen market has been experiencing significant growth in recent years, driven by several key trends:

1. Increasing Demand in Healthcare and Nutraceuticals: Collagen’s popularity has surged due to its various health benefits, including improved skin elasticity, joint health, and muscle mass. As consumers become more health-conscious, they are seeking collagen supplements and collagen-rich foods.

2. Beauty and Cosmetics Industry Growth: Collagen is a common ingredient in skincare and beauty products due to its ability to promote youthful skin and reduce wrinkles. The demand for collagen-infused cosmetics and topical treatments is on the rise, especially in the anti-aging segment.

3. Rising Preference for Natural and Sustainable Ingredients: Consumers are increasingly seeking natural and sustainable products, leading to a shift towards collagen derived from sources like fish, bovine, and poultry. This trend aligns with the growing awareness of environmental issues and animal welfare concerns.

4. Innovations in Product Formulations and Delivery: Manufacturers are developing innovative formulations and delivery methods to enhance the efficacy and convenience of collagen products. This includes collagen peptides, hydrolyzed collagen, and novel delivery systems such as powders, capsules, and functional foods.

5. Expansion of Collagen Applications: Collagen is not limited to supplements and cosmetics; its use extends to the food and beverage industry, where it is incorporated into products like protein bars, beverages, and snacks. Additionally, collagen is finding applications in pharmaceuticals, wound healing, and tissue engineering.

6. Growing Aging Population: The aging population worldwide is driving demand for products that support healthy aging and address age-related concerns such as joint pain and skin aging. Collagen supplements are increasingly popular among older demographics seeking to maintain their mobility and vitality.

7. E-commerce Growth: The rise of e-commerce platforms has made collagen products more accessible to consumers globally. Online channels provide a convenient way to purchase collagen supplements and skincare products, contributing to market growth.

Collagen Market Opportunities: Immense opportunities in developing economies

The global collagen market is experiencing substantial growth, driven by increased demand from developed economies. This surge is attributed to a shift in consumer attitudes toward collagen derivatives, with heightened awareness of their health benefits. Factors such as changing lifestyles, Western food adoption, a rising demand for functional ingredients in food, and increased industrial activity necessitating process enhancements contribute to the collagen market’s expansion in developing economies. Emerging regions like the Asia Pacific, South Africa, the Middle East, South America, and Eastern European countries offer promising opportunities for collagen market growth.

Asia Pacific is The Fastest-Growing Market for Collagen Among the Regions.

The Asia-Pacific region has emerged as the fastest-growing market in the collagen industry, driven by several key factors. A significant contributor to this growth is the increasing awareness and demand for health and wellness products among consumers in the region. With rising disposable incomes and economic growth, individuals are more inclined to invest in premium products that promote overall health, and collagen, known for its benefits to skin, hair, nails, and joint health, aligns with this trend. The aging population in many Asia-Pacific countries, including Japan and South Korea, has also played a crucial role in driving the demand for collagen, as individuals seek solutions for joint health and anti-aging. Moreover, the cultural emphasis on beauty and skincare in Asian societies has fueled the popularity of collagen-based skincare and cosmetic products. The expanding cosmetics industry, government initiatives supporting collagen use, and advancements in food technology, allowing for the inclusion of collagen in various consumables, further contribute to the region’s robust collagen market. The availability of a diverse range of collagen products, including supplements and beverages, has made it easier for consumers to integrate collagen into their daily routines, propelling the market’s rapid growth.

Top Companies in the Collagen Market

The key players in the market include Ashland (US), Darling Ingredients (US), Tessenderlo Group (Belgium), Gelita AG (Germany), Nitta Gelatin NA Inc (Japan), Nippi Collagen NA Inc (Japan), DSM (Netherlands), Titan Biotech (India), BioCell Technology, LLC (US), Vinh Hoan Corporation (Japan), Amicogen (South Korea), Collagen Solutions (UK), Weishardt Holding SA (France), Regenity (US), Lapi Gelatine S.p.a (Italy), BioCell Technology, LLC (US), Peptech Colageno do Brasil Ltda (Brazil), Athos Collagen Pvt. Ltd. (India), Kayos (India), Vital Protein LLC (US), Copalis (France), Evonik Industries (Germany), Ewald Gelatin GMBH (Germany), Sysmatese (France), and ALPSPURE LIFESCIENCES PRIVATE LIMITED (India).

Other players in the ecosystem:

Geltor (US), Viscofan Group (Spain), DAT-Schaub A/S (Denmark), SELO (Belgium), Shenguan Holdings (Group) Limited (China), Foodchem International Corporation (China), FABIOS S.A. (Poland), Fibran Group (Spain), Shandong Haiaos Biotechnology Co., Ltd (China), Crown Soya Protein Group (China), SARIA SE & Co. KG (Germany), ViskoTeepak (Denmark), Rousselot (US) (Brand of Darling ingredients), Juncà Gelatines SL (Spain), ConnOils LLC (US), and Advanced BioMatrix (part of BICO) (US).

Darling Ingredients

Darling Ingredients specializes in the development and production of sustainable natural ingredients derived from both edible and inedible animal by-products. The company serves diverse industries, including food, animal feed, fuel, bioenergy, and fertilizer, offering tailored solutions to meet specific needs. Its segments include Feed Ingredients, Food Ingredients, and Fuel Ingredients.

Within the Feed Ingredients category, Darling Ingredients collects and processes by-products from cattle, poultry, and pork. Additionally, the company gathers bakery leftovers, converting them into cookie meals in North America. Wasted cooking oil is also collected and processed into non-food grade fats. The Food Ingredients segment involves the collection and processing of porcine and bovine intestines, as well as the acquisition and processing of beef and pork bone chips, cattle hides, pig skins, and fish skins into collagen. Collagen peptides, sold under this segment through brands like Rousselot and Peptan, are utilized in various gelatin and collagen-based products for global industries and consumers.

Darling Ingredients has gained prominence in Western markets, contributing to the growth of the Nutri cosmetics industry outside Asia with its collagen peptide products. Operating in 270 plants across five continents, the company extracts value-added products, including green energy, renewable diesel, collagen, fertilizer, animal proteins and meals, and ingredients for pet food, from approximately 10% of the world’s meat industry waste streams.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=220005202

Ashland

Ashland is a global corporation specializing in the production of unique ingredients and additives, with a commitment to enhancing the world. The company actively engages with clients across diverse industries, including pharmaceuticals, personal care, architectural coatings, construction, energy, food, beverage, and nutraceuticals. Ashland emphasizes sustainability in its operations and conducts research to improve its products. The business is structured into units such as life sciences, Personal Care and Household, Intermediates and solvents, and Intersegment Sales. Within the Personal Care and household segment, Ashland Global Holdings offers collagen.

One notable product introduced by Ashland in France in 2013 is the Actopenting biofunctional, an innovative bio-engineered peptide designed based on skin structure. This product supports the skin’s natural production of dermatopontin, a vital protein crucial for restoring skin structure. Notably, Ashland’s peptide was the first commercially available product proven to enhance the presence of various proteins supporting skin structure, both in vitro and ex vivo. Operating in over 100 countries, including North America, Europe, the Asia Pacific, and Latin America, Ashland is dedicated to advancing its industry with a global reach.

Collagen Industry News

1. In April 2023, Darling Ingredients Inc. (US) completed the acquisition of Gelnex, a major global producer of gelatin and collagen products, on March 31, 2023. The acquisition, initially announced in October 2022, involved a cash payment of approximately USD 1.2 billion. With the addition of Gelnex’s five facilities in South America and one in the United States, Darling now has the capacity to produce 46,000 metric tons of gelatin and collagen products annually.

2. In April 2023, Amicogen, a biopharmaceutical and health functional food materials company, has completed the construction of a collagen and gelatin production plant in Vietnam through its joint venture with Navico, called Aminavico. The plant has a production scale of 400 tons each for collagen and gelatin, with plans to expand to 2,400 tons annually. This will help to cater the rising demand of collagen products in the region.

3. In March 2023, PB Leiner, a business unit of Tessenderlo Group, inaugurated PB Leiner (Hainan) Biotechnology Ltd., a joint venture with Hainan Xiangtai Group in China. They opened a production facility in China to increase the production of gelatin.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=220005202

About MarketsandMarkets™

MarketsandMarketsTM has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/collagen-market-220005202.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Collagen Market Size, Share, Industry Overview, Trends, Growth Drivers, Business Opportunities, and Leading Players